1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
France Human Insulin
Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
5.2.2.
By Brand (Lantus, Humulin R,
Novolin R, Humulin N, Exubera, Afrezza & Novolin N)
5.2.3. By Route
of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and
Others)
5.2.4. By Type
(Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
5.2.5. By Onset
Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long
Acting, Pre-Mixed, Inhaled)
5.2.6. By Products
(Insulin Pens, Insulin Pumps, Infusion System, Injection)
5.2.7. By
Region
5.2.8. By
Company (2023)
5.3. Market Map
5.3.1. By Indication
5.3.2. By Brand
5.3.3. By Route of Administration
5.3.4. By Type
5.3.5. By Onset Time
5.3.6. By Products
5.3.7. By Region
6.
Northern France Human
Insulin Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
6.2.2.
By Brand (Lantus, Humulin R, Novolin R, Humulin N,
Exubera, Afrezza & Novolin N)
6.2.3.
By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others)
6.2.4.
By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional)
6.2.5.
By Onset Time (Rapid Acting, Short-Acting, Intermediate
Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
6.2.6.
By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection)
7. Southern France Human Insulin Market Outlook
7.1.
Market Size &
Forecast
7.1.1. By Value
7.2.
Market Share &
Forecast
7.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
7.2.2.
By Brand (Lantus, Humulin R, Novolin R, Humulin N,
Exubera, Afrezza & Novolin N)
7.2.3.
By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others)
7.2.4.
By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional)
7.2.5.
By Onset Time (Rapid Acting, Short-Acting, Intermediate
Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
7.2.6.
By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection)
8. Western France Human Insulin Market Outlook
8.1.
Market Size &
Forecast
8.1.1. By Value
8.2.
Market Share &
Forecast
8.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
8.2.2.
By Brand (Lantus, Humulin R, Novolin R, Humulin N,
Exubera, Afrezza & Novolin N)
8.2.3.
By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others)
8.2.4.
By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional)
8.2.5.
By Onset Time (Rapid Acting, Short-Acting, Intermediate
Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
8.2.6.
By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection)
9. Central France Human Insulin Market Outlook
9.1.
Market Size &
Forecast
9.1.1. By Value
9.2.
Market Share &
Forecast
9.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
9.2.2.
By Brand (Lantus, Humulin R, Novolin R, Humulin N,
Exubera, Afrezza & Novolin N)
9.2.3.
By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others)
9.2.4.
By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional)
9.2.5.
By Onset Time (Rapid Acting, Short-Acting, Intermediate
Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
9.2.6.
By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection)
10. Eastern France Human Insulin Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Indication (Type I Diabetes, Type II Diabetes)
10.2.2.
By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera,
Afrezza & Novolin N)
10.2.3.
By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others)
10.2.4.
By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional)
10.2.5.
By Onset Time (Rapid Acting, Short-Acting, Intermediate
Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
10.2.6.
By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection)
11. Southwestern France Human Insulin Market Outlook
11.1.
Market Size &
Forecast
11.1.1. By Value
11.2.
Market Share &
Forecast
11.2.1. By Indication
(Type I Diabetes, Type II Diabetes)
11.2.2. By Brand
(Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza & Novolin N)
11.2.3. By Route
of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and
Others)
11.2.4. By Type
(Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
11.2.5. By Onset
Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long
Acting, Pre-Mixed, Inhaled)
11.2.6. By Products
(Insulin Pens, Insulin Pumps, Infusion System, Injection)
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends & Developments
13.1.
Recent Developments
13.2.
Mergers &
Acquisitions
13.3.
Product Launches
14. Policy & Regulatory Landscape
15.
Porter’s Five Forces Analysis
15.1.
Competition in the
Industry
15.2.
Potential of New
Entrants
15.3.
Power of Suppliers
15.4.
Power of Customers
15.5.
Threat of Substitute
Products
16. France Economic Profile
17. Competitive Landscape
17.1. Novo Nordisk Production SAS
17.1.1.
Business Overview
17.1.2.
Product Offerings
17.1.3.
Recent Developments
17.1.4.
Financials (As Reported)
17.1.5.
Key Personnel
17.1.6.
SWOT Analysis
17.2.
Sanofi S.A.
17.3.
Eli Lilly and Company
17.4.
wockhardt-france-sas.
17.5.
Becton Dickinson France SASU
17.6.
B. Braun Medical
17.7.
Baxter International Inc.
17.8.
Merck & Co., Inc
17.9.
Pfizer Inc.
17.10. PerkinElmer
France
18.
Strategic Recommendations
19. About Us & Disclaimer